Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Chronic Migraine Subject Is male or female, in otherwise good health, 18 to 65 years of age Has history of chronic migraine (with or without aura) according to the proposed by the Headache Classification Committee of the International Headache Society for at least 3 months prior to enrollment Has onset of migraine before age 50 Is able to differentiate migraine from any other headache they may experience (e.g., tension-type headache) Has stable history of headache for at least 3 months prior to screening Is not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period If female of childbearing potential, has a negative urine pregnancy test at Visit 1 and uses, or agrees to use, for the duration of the study, a medically acceptable form of contraception as determined by the investigator Complete abstinence from intercourse from 2 weeks prior to administration of study drug throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the study drug (a minimum of 7 days); or Surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); or  Subject Is unable to understand the study requirements, the informed consent, or complete headache records as required per protocol Is pregnant, actively trying to become pregnant, or breast-feeding Has experienced the following migraine variants: basilar migraine, aura without headache, familial hemiplegic migraine, complicated migraine, ophthalmoplegic migraine and retinal migraine Has a history of Medication Overuse Headache in the 3 months prior to study enrollment or during the Baseline Period Has abused, in the opinion of the Investigator, any of the following drugs, currently or within the past 1 year: opioids, alcohol, barbiturates, benzodiazepine, cocaine Has an unstable neurological condition or a significantly abnormal neurological examination with focal signs or signs of increased intracranial pressure Suffers from cardiovascular disease (ischemic heart disease, including angina pectoris, myocardial infarction, documented silent ischemia, or with Prinzmetal's angina); has symptoms of ischemic heart disease; have uncontrolled hypertension; has electrocardiogram (ECG) results outside normal limits for clinically stable patients as judged by the investigator Has a history of asthma, allergy, or nasal polyps developing for the first time over the age of 40 Has a history of peptic ulcer disease requiring therapeutic intervention in the year prior to study enrollment